Onboarding

Implement once, streamlined ordering after

INTERCEPT^® Fibrinogen Complex, like other blood products, is typically stored in the blood bank.

This means once inventory is available at your facility, ordering INTERCEPT Fibrinogen Complex is as simple as any other blood product.

After a one-time implementation process, INTERCEPT Fibrinogen Complex may be ordered and stored based on your facility’s needs.

Existing Customers

Cerus has partnered with BloodHub
to streamline ordering.

New Customers

Before you can place your first order through BloodHub,
we need to set you up as a new customer.

Become a Customer

Questions? Contact us here.

INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex:

INDICATIONS FOR USE

• Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
• Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.
• Second-line therapy for von Willebrand disease (vWD).
• Control of uremic bleeding after other treatment modalities have failed.

Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII.

CONTRAINDICATIONS

Contraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.

Contraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS AND PRECAUTIONS

Only the INTERCEPT Blood System for Cryoprecipitation is approved for use to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

For management of patients with vWD or factor XIII deficiency, Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used if recombinant or specific virally-inactivated factor preparations are available. In emergent situations, if recombinant or specific virally-inactivated factor preparations are not available, Pathogen Reduced Cryoprecipitated Fibrinogen Complex may be administered.